Becton Dickinson and Co (BDX)

Currency in USD
150.85
+0.29(+0.19%)
Closed·
152.28+1.43(+0.95%)
·
BDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
148.23151.72
52 wk Range
127.54187.35
Key Statistics
Prev. Close
150.56
Open
149.82
Day's Range
148.23-151.72
52 wk Range
127.54-187.35
Volume
1.79M
Average Volume (3m)
2.98M
1-Year Change
8.1445%
Book Value / Share
84.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
176.92
Upside
+17.28%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Becton Dickinson and Co News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

6 Buy
8 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 176.92
(+17.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy204.00+35.23%202.00Maintain11-05-2026
Wells Fargo
Hold161.00+6.73%157.00Maintain08-05-2026
TD Cowen
Hold163.00+8.05%189.00Maintain04-05-2026
Evercore ISI
Buy180.00+19.32%-New Coverage04-05-2026
Piper Sandler
Hold159.00+5.40%170.00Maintain17-04-2026

Becton Dickinson and Co SWOT Analysis


Strategic Separation
Explore Becton Dickinson's bold move to separate its Life Sciences division, potentially unlocking significant value and reshaping its market position.
Financial Resilience
Delve into BDX's robust financial performance, exceeding market expectations despite stock underperformance and trading near 52-week lows.
Valuation Puzzle
Uncover the intriguing valuation gap of BDX, trading below historical averages with analyst targets ranging from $185 to $280.
Future Growth Catalysts
Learn how BDX's strategic initiatives and industry positioning could drive multiple expansion and long-term shareholder value in the medical technology sector.
Read full SWOT analysis

Becton Dickinson and Co Earnings Call Summary for Q2/2026

  • Becton Dickinson Q2 2026 adjusted EPS of $2.90 beat estimates of $2.78 by 4.32%; revenue reached $4.7B, up 2.6% YoY on FX-neutral basis.
  • Stock surged 3.9% in pre-market trading to $149.63 following the earnings beat, reflecting strong investor confidence in company performance.
  • Company raised full-year EPS guidance to $12.52-$12.72, expecting low single-digit revenue growth driven by biologic drug delivery segment.
  • Adjusted gross margin declined 90 bps to 54.7% and operating margin fell 110 bps to 24.2% YoY due to tariff pressures and market headwinds.
  • CEO Polen emphasized strategic focus on innovation in patient monitoring and drug delivery despite challenges from China market dynamics and regulatory scrutiny.
Last Updated: 07-05-2026, 07:44 pm
Read Full Transcript

Earnings

Latest Release
07-05-2026
EPS / Forecast
2.90 / 2.78
Revenue / Forecast
4.7B / 4.67B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.76%
Dividend Yield
2.79%
Industry Median 1.64%
Annualised payout
4.20
Paid quarterly
5-Years Growth
+5.23%
Growth Streak

BDX Income Statement

Compare BDX to Peers and Sector

Metrics to compare
BDX
Peers
Sector
Relationship
P/E Ratio
25.2x22.3x−0.4x
PEG Ratio
−1.11−0.770.00
Price/Book
1.7x1.4x2.6x
Price / LTM Sales
1.9x1.3x3.0x
Upside (Analyst Target)
16.0%0.0%51.9%
Fair Value Upside
Unlock7.8%9.1%Unlock

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
151.12M54.84%22.75B
Other Institutional Investors
119.72M43.45%18.03B
Public Companies & Retail Investors
4.70M1.70%707.22M
Total
275.54M100.00%41.49B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.49%2,61,53,41139,37,658
Vanguard Capital Management, LLC6.71%1,84,90,61027,83,946

FAQ

What Is the Becton Dickinson (BDX) Share Price Today?

The Becton Dickinson share price today is 150.85.

What is the current Becton Dickinson (BDX) share price and day range?

As of 10-07-2026, the Becton Dickinson share price is 150.85, with a previous close of 150.56. The share price has ranged from 148.23 to 151.72 today, while the 52-week range spans from 127.54 to 187.35.

What Is the Becton Dickinson Market Cap?

As of today, Becton Dickinson market cap is 41.57B.

Does Becton Dickinson Pay Dividends? What's The Current Dividend Yield?

The Becton Dickinson dividend yield is 2.78%.

What Is the Becton Dickinson (BDX) Share Price Target?

The average 12-month share price target for Becton Dickinson is 176.92, with a high estimate of 225 and a low estimate of 150. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +17.28% Upside potential.

What Is Becton Dickinson's Earnings Per Share (TTM)?

The Becton Dickinson EPS (TTM) is 5.76.

When Is the Next Becton Dickinson Earnings Date?

Becton Dickinson will release its next earnings report on 30-07-2026.

From a Technical Analysis Perspective, Is BDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Becton Dickinson Trade On?

Becton Dickinson is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Becton Dickinson?

The stock symbol for Becton Dickinson is "BDX."

How Many Times Has Becton Dickinson Stock Split?

Becton Dickinson has split 5 times.

How Many Employees Does Becton Dickinson Have?

Becton Dickinson has 72000 employees.

What Is the BDX Premarket Price?

BDX's last pre-market stock price is 152.80. The pre-market share volume is 470.00, and the stock has changed by 2.24, or 1.49%.

What Is the BDX After Hours Price?

BDX's last after hours stock price is 152.28, the stock has changed by 1.43, or 0.95%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.